UNSPSC 51102839: Clioquinol/hydrocortisone/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE250. This VA Drug Class (DE250) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL.

UNSPSC 51102839 Clioquinol/hydrocortisone/pramoxine is a Commodity code, but the recent state and local solicitations tagged under it do not actually procure this topical pharmaceutical combination; instead, they solicit naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The code shows a substantial mismatch between its nominal scope and the work actually being bought. State and local procurement of pharmaceuticals and medical supplies—the broader family these opportunities represent—comes from health departments, fire departments, city purchasing offices, and state HHS agencies through IFBs, RFPs, and RFIs; issuing bodies range from county health systems to statewide cooperative purchasing alliances that aggregate demand across participating jurisdictions.

Activity appears concentrated in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 drug deactivation systems annually with a response deadline of July 26, 2023 (note: the date appears inconsistent in the source). The City of Tampa's Purchasing Department issued IFB 26P00145 on March 25, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a sealed-bid deadline of March 13, 2026, an estimated contract value of $700,000, and a SLBE set-aside with a 5% bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026, response deadline, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon.